Cargando…

Personalised Medicine—Implementation to the Healthcare System in Europe (Focus Group Discussions)

Background: Personalized medicine (PM) is an approach based on understanding the differences between patients with the same disease and represents a change from the “one size fits all” concept. According to this concept, appropriate therapies should be selected for specific groups of patients. PM ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Stefanicka-Wojtas, Dorota, Kurpas, Donata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058568/
https://www.ncbi.nlm.nih.gov/pubmed/36983562
http://dx.doi.org/10.3390/jpm13030380
_version_ 1785016662796271616
author Stefanicka-Wojtas, Dorota
Kurpas, Donata
author_facet Stefanicka-Wojtas, Dorota
Kurpas, Donata
author_sort Stefanicka-Wojtas, Dorota
collection PubMed
description Background: Personalized medicine (PM) is an approach based on understanding the differences between patients with the same disease and represents a change from the “one size fits all” concept. According to this concept, appropriate therapies should be selected for specific groups of patients. PM makes it possible to predict whether a particular therapy will be effective for a particular patient. PM will still have to overcome many challenges and barriers before it can be successfully implemented in healthcare systems. However, it is essential to remember that PM is not a medical revolution but an evolution. Methods: Three focus groups were conducted, to achieve the purpose of this study, which was to identify the barriers and facilitators existing to the implementation of PM and to highlight existing practices in European countries. Focus group discussions covered the areas of barriers and facilitators to the implementation of personalized medicine. Results: This section describes the results of the focus groups that covered the areas of barriers and facilitators of personalized medicine implementation. Conclusions: Personalized medicine faces many challenges and barriers before it can be successfully implemented in health systems. The translation of PM to European countries, differences in regulations, high costs of new technologies, and reimbursement are the reasons for the delay in PM implementation.
format Online
Article
Text
id pubmed-10058568
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100585682023-03-30 Personalised Medicine—Implementation to the Healthcare System in Europe (Focus Group Discussions) Stefanicka-Wojtas, Dorota Kurpas, Donata J Pers Med Article Background: Personalized medicine (PM) is an approach based on understanding the differences between patients with the same disease and represents a change from the “one size fits all” concept. According to this concept, appropriate therapies should be selected for specific groups of patients. PM makes it possible to predict whether a particular therapy will be effective for a particular patient. PM will still have to overcome many challenges and barriers before it can be successfully implemented in healthcare systems. However, it is essential to remember that PM is not a medical revolution but an evolution. Methods: Three focus groups were conducted, to achieve the purpose of this study, which was to identify the barriers and facilitators existing to the implementation of PM and to highlight existing practices in European countries. Focus group discussions covered the areas of barriers and facilitators to the implementation of personalized medicine. Results: This section describes the results of the focus groups that covered the areas of barriers and facilitators of personalized medicine implementation. Conclusions: Personalized medicine faces many challenges and barriers before it can be successfully implemented in health systems. The translation of PM to European countries, differences in regulations, high costs of new technologies, and reimbursement are the reasons for the delay in PM implementation. MDPI 2023-02-21 /pmc/articles/PMC10058568/ /pubmed/36983562 http://dx.doi.org/10.3390/jpm13030380 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Stefanicka-Wojtas, Dorota
Kurpas, Donata
Personalised Medicine—Implementation to the Healthcare System in Europe (Focus Group Discussions)
title Personalised Medicine—Implementation to the Healthcare System in Europe (Focus Group Discussions)
title_full Personalised Medicine—Implementation to the Healthcare System in Europe (Focus Group Discussions)
title_fullStr Personalised Medicine—Implementation to the Healthcare System in Europe (Focus Group Discussions)
title_full_unstemmed Personalised Medicine—Implementation to the Healthcare System in Europe (Focus Group Discussions)
title_short Personalised Medicine—Implementation to the Healthcare System in Europe (Focus Group Discussions)
title_sort personalised medicine—implementation to the healthcare system in europe (focus group discussions)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058568/
https://www.ncbi.nlm.nih.gov/pubmed/36983562
http://dx.doi.org/10.3390/jpm13030380
work_keys_str_mv AT stefanickawojtasdorota personalisedmedicineimplementationtothehealthcaresystemineuropefocusgroupdiscussions
AT kurpasdonata personalisedmedicineimplementationtothehealthcaresystemineuropefocusgroupdiscussions